Androgen Receptor Degraders Overcome Common Resistance Mechanisms Developed During Prostate Cancer Treatment
收藏NIAID Data Ecosystem2026-03-11 收录
官方服务：
资源简介：
RNA-sequencing of VCaP and LNCaP, LNCaP-EnzR, or LNCaP AR-V7 overexpressing prostate cancer cell lines treated with AR degrader ARD-61. VCaP cells treated with 100nM ARD-61 or DMSO control for 6 hours, and LNCaP, LNCaP-EnzR, or LNCaP AR-V7 cells treated with 100nM ARD-61b for 24 hours
创建时间：
2020-01-14
